24.03.30 () 00:08

Dailypharm

X
ı ҿ ,
ϸ 2017-05-13 06:14:50
ı ҿ ,
ϸ 2017-05-13 06:14:50
ü , 漼



[2] 漼

츮 ȸ dz ԰Ÿ ̵ ڵȭ ο ÿ ̻ ü ׻ ׿ 缺 ȯ ϵ ġ ȯ ߺ μӿ ִ. ̿ Ȳ ذ コɾ ־ ߿ ٽɰ ϳ ƴ.

׷ Ϸ绡 񸸿 Żϰ ϴ п پϰ ǰ ִ ȫӿ δ κ ü ִ. ȯ ɰϴ. ü ع 翬 ԰ ̴ ̴. ׷ ׷ µ鿡 ο ϰ ư ʱ⿡ ãƾ ʿ䰡 ִ. ̷ 翬ϸ鼭 ġ ȭ ̷ϴ ü Ư¡̴. ܼ ſ ƴϴ. ü Ư¡ ϱ? ׸  ؾ ϴ°ϱ?

4 Queensland University of Technology Institute of Health and Biomedical Innovation Faculty of Science and Engineering Saba Farnaghi ڻ ROLE OF HYPERCHOLESTEROLEMIA IN OSTEOARTHRITIS DEVELOPMENT ſ ǹִ ߴ. ұϰ ü߿ ̻ ı ȯ ΰ ִ ɸ Ǵ ϴ . , ༺ (, OA) ߺ ̻ ģ 뿡 θ ̴. ڴ apolipoprotein E- (ApoE−/−) ̿ ݷ׷ ߽Ų 𵨿 proteoglycans collagen ս, aggrecan( ϴ ֿ chondroitin sulfate ϴ proteoglycan) ı, Ȱ׸ , () , ϰ ȭ , ׸ ᱹ ı ̻ ͰǴ Ұߵ ߴ. ݿ Ŀ 麸 ̵ 豺(̻, ) 鿡 ȭƴ. , ° ܵ帮 , Ȱ ׻ ıϴ Ŀ ڷμ ߱ ̴. ̴ atorvastatin ܵ帮Ƹ Ȱ κ ȣϴ mitochondria targeted anti-oxidants (mito-TEMPO, MitoQ) ȭ Ʈ ȸ ̻ ϴ ȭ ߴ. ׷ ڴ ̻(ݷ׷) 缺 ڵ ܵ帮ƿ ȭ Ʈ ۿ ȭ״ٸ鼭 ġῡ ־ Ǵ Ȱ ġᰡ ߿ϴٰ ߴ.

׷ٸ Ȯϰ  ı ҵ  Ŀ ̷ 2 ȯ ߺ Ǵ ȭŲ ϱ?

Ҹ ұ ʷϴ ü ū Ư¡̸ 漼 (adipogenesis) Ǵ ̷. Adipogenesis 漼ü(pre-adipocyte) 漼(adipocyte) ȭ(differentiation) ܰ ġµ, ̶ ٽ ϴ peroxisome proliferator activated receptor (PPAR)̴. PPAR Ȱ ( տ ȰȭǾ 縦 ϴ , ligand activated trascription factor family) ϸ Ǵ 濡 ̳ ȴ. ̴ 漼ü(Ǵ Ƽ) 漼 ȭǴµ ʿ 漼 ռ 忡 䱸Ǵ ܹ Ǵ ڵ ۵Ű ϰ ȴ.

漼 ȭ ù° ܰ CCAAT enhancer–binding proteins C/EBP & , glucocorticoid receptor(GR), signal transducer & activator of transcription 5A(STAT5A), cAMP-response element-binding protein(CREB) ڱ Ǹ ̵鿡 Ȱȭ ٸ ڵ PPAR2 C/EBP ι° ܰ踦 漼 α׷(adipocyte gene programing) ϰ ȴ. ̷ ü chromatin ̵ ڵ ټ(chromatin ) 䱸Ǵµ 漼 ʱ ܰ迡 Ͻ Ͼ ְ 漼 ϰ ȴ. ׷ C/EBP ù° ܰ迡 chromatin ۿϴ ˷ ִ.

׷ ᱹ 漼 ο ¿ȴٰ Ѵ. ׸ ̶ ٽ PPAR㰡 ϰ ȴ. 漼 ο 4ܰ , uptake of metabolic substrate( ), lipogenesis( ), lipolysis (), lipid export ( ) ְ ܰ迡 PPAR㰡 ϰ ִ.

漼 ̿Ǵ 1 metabolic substrates() glucose, triacylglycerol(TAG), long chain fatty acids(LCFAs) شǸ, 漼 LCFA ٽ TAG ȯ perilipin ȭ ü ϰ Ǹ鼭 ñ (lipogenesis) Ͱȴ. ݸ (lipolysis) ִ (TAG) θ ȣϰ ִ perilipin иϿ lipase ۿ ְ ϴ ʿϸ ̷ ҾTAG cytosolic lipase diacylglycerol Ǵ monoacylglycerol صȴ ̷ ظ LCFA (lipid export) Ȯϰ ˷ յ flipper protein ִ δٰ Ѵ. ó 漼substrate uptake lipogenesis , lipolysis lipid export ҿ ¿ǹǷ ߿ϴ.

׷ PPAR̴, PPAR , , , ݱ, ַ Ǹ eicosanoidfree fatty acid ȰȭǴµ, ٷ fibrate ๰ ̿ ۿϿ HDL TG ҽ 󵿸ȯ ġ ȴ. ȭ ʿ ڵ ̿ ִ. PPAR, 淮 ҿ ȭ ϴ ڷμ Ѵ. PPAR ȭ ϴ ܹ ۿ ܵ帮Ƴ UCP(¦Ǯ ܹ) ߻, Ҹ ϴ ڵ 縦 ϴ ̵ ۿ ½Ű ġ Ÿ ִ.

ٽ, PPAR ռ ó 漼(adipogenesis) ȭ Ĺݺο Ÿ 漼üܰ迡 ϴ Ȱȭ Ǹ 翡 õ پ ڵ ϱ Ѵ. 漼 lipoprotein lipase (LPL) к TG(triglyceride) LCFA(long chain fatty acid) CD36 FATP1(fatty acid transfer protein 1) Ʈ͸ ̵ LCFA 漼 ´.

漼 aP2 ˷ FABP4 Ÿµ ̴ LCFA ģȭ 漼 κ LCFA ̿ յǾ ϰ ִ. ̷ LCFA TG ȯ perilipin ü ̷ ȴ. Perilipin TG ü ִ · ϸ鼭 ȭ۵ ⿩ PKA(protein kinase A) λȭ Ǵ ̻ ȣ ϰ (lipolysis) Ͼ ȴ.

˷ ִٽ PPAR glucose metabolism ڵ鿡 õ ִ. Ư Phosphoenolpyruvate carboxy kinase (PEPCK) 漼 pyruvate glycerol-3-phosphate (G3P) ȯ ϱ⿡ 漼 TG(triglyceride) 忡 ־ ٽ Ѵ Pyruvate dehydrogenase (PDH) ݴ pyruvate acetyl-co A ϴµ ֿ ȭ , 漼 ٸ ȿ pyruvate dehydrogenase kinase 4 (PDK4) ̷ PDH Ȱ Ͽ TG ϰ ȴ. ̷ PEPCK Բ, ȭ(acetyl-coA) G3Pռ pyruvate ٲ ´. Ż(gluconeogenic pathway) G3P ռ 漼 glycerol 3 kinase ̵ ְ glycerol G3Pռ ⿡ ߿ϴ. PPAR (glycolysis) glucokinase (GK) 6- phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3)͵ õ ִ.

ϸ Ȱȭ PPAR substrate uptake LPL, CD36, FATP1, lipogenesis FABP4, PEPCK, GK, PFKFB3, Perilipin, ׸ PDH ϴ PDK4 ̵ 漼 漼ü ȭӸ ƴ϶ ȣ ߿ ϴ ̴. 漼 PPAR ռ ϰ ǰ е (glycolysis) ռ ϰ ȴ. , ̿ ׸ 漼 ɼ 漼 ̴. Ƽ(thiazolidine) üPioglitazone PPAR 㸦 ڱؼ ν 索 ü ۿ ִ ȴ.

׷ ̷ 漼 Ư¡ PPAR㸸 ƴϴ. ׷ٸ ̿ Ȳ ڵ鿡 Ŀ ϱ ϱ?
ϸ (dailypharm@dailypharm.com) ٸ
  • μ
  • īī
  • ̽
  • Ʈ
  • 0
/home/dailypharm/issueData2017/
ǰ
0
͸ǰ | Ǹǰ߾ Ģ
ݱ

Ǹ ͸ , Ǹ ̸ ̵ ˴ϴ. ͸ ʸ ϸ, ͸ մϴ.

ڹ(-ڴϾ-ʱ ) ˵ ϸ ȸ Խ ⡯ ĺ Ʈ ׻ ֻܿ ˴ϴ. ο ø Ϲȸ Խ ĺ ڴϾ ȸ ϴܿ ǽð ˴ϴ.

뺸 ϰ ̵ ̿ Ǵ ֽϴ.

  • ۱ǡΰݱ Ÿ Ǹ ħϴ

    α׷ ϰ , ȳϴ Խù

    Ÿ Ǵ 3 ۱ Ÿ Ǹ ħ Խù

  • ٰ 桤 Ѽϴ Խù

    Ư ̿ ο ν 弳

    Ư 븳 ϴ

    Ȯ ȵ ҹ Ű

    弳 , Ӿ

    Ź, ɿ ˵Ǵ ( û )

    Ư ̳ ü ϴ

    Ư ѼϿ ش ûϴ

    Ư (ֹεϹȣ, ȭ, ּ ) Խϴ

    Ÿ ID Ȥ г ϴ

  • Խ Ư ѵǴ

    ʴ

    翡 ߺ

    κ Ͽ ݺ ϴ 쵵

    Խù,

    Ե Խù

    Խù б

  • û ִ

  • Ÿ

    ʿ伺 ̸

    Ÿ ˵Ǵ 縦

    Ÿ  ڰ ʿϴٰ ǴܵǴ

  • Ȯ

    ۱ڷκ , , ϴ

    Ÿ ʻ ħϰų ϴ

    翡 ̿ (Ÿ ID, йȣ )

  • ̻ Ϻ ׿ ̿ 縦 , Ρ ó ֽϴ.

    õ ̴ ҹ Ǵܵǰų ϸ 񽺿 ٶ ʴٰ ǴܵǴ ġ ϰڽϴ.

    رŸ ϸ ڿ ֽʽÿ. ּҴ dailypharm@dailypharm.comԴϴ.

ֽż ݴ
౹ Ϲݾ Top 100(03)
ǰ Ƚ Ǹűݾ
1 Ÿ̷500mg(10) 23638 33104 101,505,000
2 Ȱť 13391 83427 97,389,700
3 Ǹť 10902 91595 73,069,159
4 ݿ 11997 88325 71,846,700
5 ũũ 4431 4720 52,151,000
6 뽺ī 20g 2332 2418 49,544,700
7 319 12291 44,946,300
8 Ź ĸ(10ĸ) 10732 15961 42,562,800
9 S 676 1227 42,429,350
10 ݴ ť÷ 8546 11210 42,423,060
11 ̰źĸ(60ĸ) 1292 2602 37,202,100
12 ġ 8140 41776 36,792,300
13 öŸ(34) 2501 3833 35,705,600
14 ׶÷ ƮŸ 3353 4312 35,035,660
15 Ʒγΰ̾(120) 657 810 34,246,900
16 ġ̽Ʈġ120g 2388 3282 34,107,490
17 öŸ(40) 2100 2586 34,093,300
18 ٿ 30g 2899 5594 33,943,700
19 (120) 1218 2384 32,914,000
20 ڶ-(40) 1737 3804 28,306,900
21 Ժ 5110 8423 27,914,600
22 Ź 3783 5019 27,081,000
23 ƽŸ 434 825 26,872,500
24 ׶÷ ݵ& Ʈ 1824 2172 25,848,300
25 (10) 8429 12233 25,619,101
26 ȲûɿŹ50ml(õ) 1192 2335 25,361,000
27 ݴ ݵť÷ 5324 6920 25,224,900
28 Ÿ̷500mg(30) 2468 3258 24,699,390
29 Ľõ򿬰10׶ 3091 3369 24,306,500
30 6089 25744 24,196,461
31 Ʒ 3226 7806 24,186,252
32 6̺(30ĸ) 2737 3245 23,701,750
33 ġ̽Ʈġ150g 1401 1754 23,469,900
34 ũ 1907 1963 23,302,401
35 λ絹÷(100) 671 1981 22,752,400
36 ݿ 5552 7933 22,665,600
37 ťýȾ0.5ml*60 1158 1319 22,004,000
38 D-׳ 2074 2207 21,799,902
39 Ľõ򿬰5g 3700 3954 20,580,200
40 뽺ī 10g 1603 1663 20,406,600
41 ӽ÷ 1879 2250 20,176,000
42 öŸ 3232 7567 19,371,321
43 ȲûɿŹ50ml() 1585 3803 19,128,000
44 Ȳûɿȯ() 255 1579 19,058,500
45 ƽƮ(150) 195 351 18,535,100
46 Ÿ̷8ð̾˼ 4493 6574 18,407,000
47 ʽ÷÷ 2748 3217 18,376,001
48 īɾ10g 2552 2817 18,221,600
49 Ʒγΰ(100) 525 1187 18,136,800
50 (10) 2814 3718 18,035,700
51 6̺꿬ĸ(10ĸ) 4711 6546 17,234,600
52 ھ ߽20ml 1500 1754 17,208,900
53 ƽŸ 313 594 16,459,972
54 ݴŰ÷ 3393 4385 15,960,800
55 ̵Ⱦ 14ml 2463 2769 15,949,650
56 ǥȲûɿ 50ml 1061 3758 15,544,646
57 ڷƮ 2mg (Ʈ) 693 1630 15,516,200
58 Ź 2643 3839 15,388,600
59 ѺŸC1000mg 814 2828 15,249,703
60 λ絹÷(270) 194 737 15,225,500
61 밢()(18) 1795 2220 15,094,100
62 ̵Ⱦ 14ml 2416 2576 14,910,600
63 λ絹(100) 491 907 14,826,800
64 ׺ƽĸ 294 546 14,789,500
65 翬ĸ(120ĸ) 372 387 14,722,300
66 Ź̵ 3100 3837 14,720,200
67 Ʈ0.1%й 1182 1495 14,673,700
68 ȭ 4074 18105 14,639,465
69 Ʒ 2856 4634 14,629,300
70 ѽŻ÷(10) 3458 5196 14,582,200
71 ׺ǵ 1246 7135 14,399,712
72 ݴŰ÷ 3107 3696 14,384,750
73 ÷ 3969 4682 14,254,868
74 ƼǪīŸö󽺸 2531 4745 13,924,700
75 ̵Ⱦ׼ 14ml 2151 2411 13,871,800
76 īٿĸ(60ĸ) 299 427 13,498,500
77 ΰ 155 206 13,325,000
78 2480 9352 13,106,010
79 ξ 487 5011 13,096,210
80 ƼǪ Ŀ 1714 3762 13,033,911
81 īɾ 6g 2647 2864 12,758,350
82 10 1610 2720 12,753,338
83 ƽúŰ÷(10) 2340 2566 12,706,610
84 ġĸ(60ĸ) 452 984 12,697,600
85 տ翬ĸ(80ĸ) 349 449 12,559,600
86 Ǫ÷ 3092 4079 12,536,300
87 īڿ;(300) 425 459 12,408,600
88 Ÿ̷ݵ忡 2519 3686 12,349,800
89 2% 120ml 683 707 12,166,600
90 ġĸ(120ĸ) 241 251 12,094,000
91 ȯ 1945 2815 12,000,300
92 Ŭƾ 972 1013 11,992,500
93 ƼǪ Ŀ 1949 4686 11,989,100
94 ݴ ť÷ 2523 3104 11,948,900
95 ǥȲûɿ50ml(õ⺯) 584 1190 11,875,100
96 1100 1463 11,805,800
97 ؽ 1141 1198 11,802,000
98 ڸŰĸ 2134 2516 11,677,500
99 Ⱦ0.5ml 573 659 11,636,000
100 ƮƮŰ& 1615 2330 11,516,140
ü



ͳݽŹϹȣ: 00048 | 2005.09.09 | 2005.09.09 | : | : ȣ
ּ: ı 128 SK V1 GL ƮνƼ A 401ȣ
ȭ : 02-3473-0833 |ѽ : 02-3474-0169 | ûҳ⺸ȣå(å ű)
Contact dailypharm@dailypharm.com for more information
ϸ () ϴ ۱ǹ ˵Ǹ, 縦 ֽϴ.